These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 19479148)

  • 41. Etanercept therapy for severe plaque psoriasis in a patient who underwent a liver transplant.
    Hoover WD
    Cutis; 2007 Sep; 80(3):211-4. PubMed ID: 17956009
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TNFalpha and its receptors in psoriatic skin, before and after treatment with etanercept.
    Caldarola G; De Simone C; Carbone A; Tulli A; Amerio P; Feliciani C
    Int J Immunopathol Pharmacol; 2009; 22(4):961-6. PubMed ID: 20074459
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Erythrodermic psoriasis: current and future role of biologicals.
    Stinco G; Errichetti E
    BioDrugs; 2015 Apr; 29(2):91-101. PubMed ID: 25752640
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biological therapy for psoriasis.
    Clements SE; Abdul-Ghaffar S; Griffiths CE
    Br J Hosp Med (Lond); 2006 Apr; 67(4):184-7. PubMed ID: 16681304
    [No Abstract]   [Full Text] [Related]  

  • 45. Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.
    Costanzo A; Talamonti M; Botti E; Spallone G; Papoutsaki M; Chimenti S
    Dermatology; 2009; 219(1):48-53. PubMed ID: 19372639
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Biological therapy for psoriasis: practical experience at a French dermatology unit].
    Saccomani C; Penz S; Guerre-Schmidt R; Riou MO; Pelletier F; Puzenat E; Mermet I; Levang J; Humbert P; Aubin F
    Ann Dermatol Venereol; 2009 Dec; 136(12):877-82. PubMed ID: 20004312
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases.
    Famenini S; Wu JJ
    J Drugs Dermatol; 2013 Aug; 12(8):939-43. PubMed ID: 23986169
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Etanercept-induced asthma in a psoriatic patient resolving with transition to ustekinumab.
    Torres T; Vilaça S; Velho G; Selores M
    Eur J Dermatol; 2012; 22(5):696-7. PubMed ID: 22910198
    [No Abstract]   [Full Text] [Related]  

  • 49. Monitoring biologics for the treatment of psoriasis.
    Papp KA
    Clin Dermatol; 2008; 26(5):515-21. PubMed ID: 18755370
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
    Woolf RT; Smith CH; Robertson K; Barker JN
    Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
    [No Abstract]   [Full Text] [Related]  

  • 51. Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases.
    Trent JT; Kerdel FA
    Dermatol Nurs; 2005 Apr; 17(2):97-107. PubMed ID: 15916184
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term management of erythrodermic psoriasis with anti-TNF agents.
    Romero-Maté A; García-Donoso C; Martinez-Morán C; Hernández-Núñez A; Borbujo J
    Dermatol Online J; 2010 Jun; 16(6):15. PubMed ID: 20579470
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
    Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
    Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Systemic therapies for psoriasis: understanding current and newly emerging therapies.
    Sobell JM; Hallas SJ
    Semin Cutan Med Surg; 2003 Sep; 22(3):187-95. PubMed ID: 14649586
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Successful treatment of hidradenitis suppurativa with infliximab in a patient who failed to respond to etanercept.
    Poulin Y
    J Cutan Med Surg; 2009; 13(4):221-5. PubMed ID: 19706231
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Survival rate of etanercept for psoriasis in real life: a multicentre observational study.
    Herrera-Acosta E; Suárez-Pérez JA; Aguilera J; Gómez-García F; Jiménez-Puya R; Guimerá F; Mendiola MV; Herrera-Ceballos E
    Eur J Dermatol; 2014; 24(5):619-20. PubMed ID: 25115194
    [No Abstract]   [Full Text] [Related]  

  • 58. Effective control of psoriasis by etanercept in a patient with HCV-related diseases.
    Piccolo D; Di Cesare A; Fargnoli MC; Paoloni M; Vecchiotti S; Peris K
    Eur J Dermatol; 2008; 18(4):459-60. PubMed ID: 18573723
    [No Abstract]   [Full Text] [Related]  

  • 59. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM; Bottino CJ; Lindholm J; Buchholz R
    J Drugs Dermatol; 2005; 4(5):544-55. PubMed ID: 16167412
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biologic treatments for psoriasis.
    Kipnis CD; Myers WA; Opeola M; Gottlieb AB
    J Am Acad Dermatol; 2005 Apr; 52(4):671-82. PubMed ID: 15793519
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.